Preliminary results from the first six patients taking part in a Phase One trial surprised and delighted the Oxford University team.
Although the trial was only designed to test safety and dosages, two men with relatively advanced disease experienced dramatic improvements to their eyesight.
The researchers are now planning a larger Phase II trial that will focus on the therapy's effectiveness.
More top news
Health workers are set to be given a 1% pay rise, the Government has announced.
Facebook app rolls out new Snapchat-like camera features allowing users to create and share 'stories' and add filters and masks to images.
Wet weather incoming